Equillium, Inc. (EQ) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29446K1060
Equillium, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -23.63 m USD |
| EBIT | -23.23 m USD |
| Net income | -22.40 m USD |
| Diluted EPS – continuing operations | -0.39 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
More stocks
- Munsin Garment (2916.TWO)
- HusCompagniet AS (HUSCO.CO)
- OGX GROUP BERHAD (0395.KL)
- Hwa Fong Rubber (Thailand) Public Company Limited (HFT.BK)
- Celxpert Energy (3323.TWO)
- Leishen Energy Holding Co., Ltd. Ordinary Shares (LSE)
- GIIR Inc (035000.KS)
- Insight Molecular Diagnostics Inc. (IMDX)
- Wellell Inc (4106.TW)
- SKYX Platforms Corp. (SKYX)
- G J Steel Public Company Limited (GJS.BK)
- Vaziva Sa (ALVAZ.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.